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Our experience of surgical treatment of small-cell lung cancer
Jackevicius, Algirdas K.; Cicenas, S;. Askinis, R.; Pipiriene-Zelviene, 
J.; Mickevicius, R. 
Institute of Oncology Vilnius University, Vilnius, Lithuania
Objective: to analyse the follow-up results of treatment of small-cell 
lung cancer (SCLC) during period 1980-2005 years. There are many 
controversies about the surgical treatment of SCLC.On the other hand, 
other authors report a survival of 33% of ﬁve years in the ﬁrst stage of 
the disease.
Materials and Methods: In Thoracic Clinic of Institute of Oncology 
Vilnius University 2640 patients (pts) with lung cancer were treated 
surgicaly in the course of 1980-2005 years. In 220 cases small- cell 
lung cancer was diagnosed. The distribution of pts according to 
TNM classiﬁcation were: 6 pts had T1N0M0, 36pts- T2N0M0, 10pts 
- T3N0M0, 48pts - T1-2N1M0,12pts - T3N1M0, 60pts - T1,2N2M0, 
5 pts- T4N1M0, 28pts - T4N2M0, in 15 pts distant metastases were 
detected after operation. The most common operation was lobectomy 
which have performed 79 pts, pneumonectomy - 55, bilobectomy -26, 
segmentectomy, wedge resection-6 and in 54 cases was performed only 
explorative thoracotomy. In 4 cases tumor was removed during VATS 
surgery. 177 pts have received additional treatment (chemotherapy, 
radiotherapy), before surgery 50 pts and after operation -129. Some pts 
have received both methods of conservative treatment
The satisfactory results were received in early stages of the disease, 
who were underwent lobectomy and received adjuvant therapy: median 
survival was 35.6 months. The pts after pneumonectomy lived 22.2 
months.
Conclusions: 
1. The surgical treatment could perform only in cases of early stages 
(I-II) of small- cell lung cancer.
2. After operation intensive adjuvant chemotherapy(5-6 cycles) must 
be used in all cases (N0 and N+). The pts with N2 after chemothera-
py must be treated with radiotherapy.
3. The staging of the tumor before surgery during surgical intervention 
is most important factor for suitabale treatment of pts with small- 
cell lung cancer
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Exploration of multidisciplinary therapy including surgery in 
Limited Disease (LD) stage small cell lung cancer (SCLC): a 
clinical report of 122 cases from single institute
Shi, Yuankai1 Wang, Huijie2 Sun, Kelin2 Zhang, Xiangru2 Sun, Yan1 
1 ASCO, Beijing, China 2 CSCO, Beijing, China 
Backgroud: Small cell lung cancer (SCLC) is a systemic disease 
which is rarely cured with surgical resection. At present, Surgery alone 
for SCLC is no longer used as standard therapy; standard management 
of SCLC has included chemotherapy or chemotherapy combined with 
irradiation. The role of surgery remains uncertain,However, Several 
studys revealed that surgery could improved outcome of Limited 
disease SCLC.
Methods: To explore the survival outcome of LD SCLC treated with 
multidisciplinary therapy including surgery. Patients with LD stage 
SCLC treated with multidisciplinary therapy including surgery were 
reviewed retrospectively.
Results: Between Jan 1999 and Dec 2004, 122 patients(pts) SCLC 
treated with multidisciplinary therapy including surgery: male 98, 
female 23; medium age 57(32-81); Pneumonectomy 40 pts, lobectomy 
97 pts and limited resection 3 pts; R0 resection 96 pts, R1 resection 
16 pts and palliative resection 11 pts. Postoperative stage: stage IA 4 
pts,stage IB 25 pts, stage IIB 25, stage IIIA 52 pts and stage IIIB 16 
pts. Two pts died within 1 month after operation, 4 pts treated with 
surgery alone, 2 only received surgery and postoperative radiation, 
3 pts received chemotherapy followed by surgery and postoperative 
chemotherapy (CT+S+CT), 92 pts surgery followed by postoperative 
chemotherapy,and 19 received surgery followed by combined chemo-
radiation. Median survival time (MST) of overall patients is 38 months, 
the 1-,3-,5 year survival rate was 83.6%, 50.0%, and 38.0%, respec-
tively. For 4 pts treated surgery alone, survival time was 13,13.5, 60+ 
and 71+ months respectively, survival time of pts treated with post-
operative radiation alone were 10 and 40+ months, the survival time 
of pts treated with CT+S+CT was 7.7, 47 and 26+ months. For 92 pts 
received postoperative chemotherapy and 19 patients received postop-
erative chemoradiotherapy, the MST was 40.6 months and 28 months, 
5 year survival rate was 38.2% and 40.5%, respectively. According 
to TNM stage system,the MST of stage IA and IB were not reached, 
for stage IIB, IIIA and IIIB was 52 months, 22 months and 13 months 
(P=0.007), respectively. 
Conclusion: Our data showed that LD stage SCLC treated with mul-
tidisciplinary therapy had better survival time, and surgery may play 
more important role in the management of LD stage SCLC. 
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A message of hope: creation of the Faces of Lung Cancer Project 
for increasing awareness of clinical trials
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Williams, Charles3 Bepler, Gerold1,3 Zheng, Zhong5 
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Objective: In 2002, the Thoracic Oncology Advocacy Program at H. 
Lee Mofﬁtt Cancer Center and Research Institute was created with 
a mission to contribute to the prevention and cure of lung cancer by 
embracing the patient perspective. In an effort to increase awareness of 
clinical trials and to humanize the clinical trial process, members of the 
